Daclatasvir Dihydrochloride helps fight persistent viral infections. Reducing the virus's ability to survive allows for improved immune health without widespread damage to healthy systems.
When the hepatitis C virus tries to multiply, it relies on a protein called NS5A to assemble new viral particles. Daclatasvir Dihydrochloride belongs to the class of NS5A inhibitors, a group of medicines that interfere with this viral step. Its primary therapeutic role is to help control chronic hepatitis C infection by reducing the amount of virus in the body.
This active compound is found in products such as Natdac and Daclatasvir, which are marketed in Singapore. Like other antiviral agents, it is used as part of a combination regimen aimed at achieving a sustained reduction of viral load.
The chemical form, Dihydrochloride, improves the stability of the compound, allowing it to be formulated as oral tablets that patients can take at home.
Across Singapore, patients may encounter Daclatasvir Dihydrochloride in medicines like Natcad and Daclatasvir. Both are supplied as oral tablets, typically 30 mg or 60 mg strengths, designed for once-daily use.
In the local market, the tablets are available under generic names as well as brand names, with the same active ingredient but different packaging. Whether purchased from a hospital pharmacy or a private outlet, the ingredient content remains consistent across these formulations.
These products are part of the broader range of Daclatasvir Dihydrochloride medications approved for hepatitis C therapy in Singapore.
For individuals living with chronic hepatitis C, this medication is used to address ongoing viral replication. It is commonly prescribed for several hepatitis C genotypes, especially genotype 1, 2, 3, and 4.
Patients with compensated liver cirrhosis may receive it as part of a regimen to lessen disease progression. It is also employed in people who have previously undergone other antiviral treatments but need a new approach.
In addition, the drug can be combined with other direct-acting antivirals to enhance overall viral clearance, offering a broader therapeutic option for diverse patient groups.
By attaching to the viral NS5A protein, Daclatasvir Dihydrochloride blocks a crucial step in the virus’s life cycle. This interruption prevents the virus from forming new copies efficiently, leading to a drop in viral levels in the bloodstream.
The effect is achieved without directly killing liver cells, so the medication mainly works by limiting the virus’s ability to spread within the body.
Mild and short-term sensations such as headache, fatigue, nausea, or mild gastrointestinal upset are frequently reported. These symptoms usually resolve on their own and do not require medical intervention.
Rarely, patients may experience signs of severe liver injury, such as yellowing of the skin or eyes, dark urine, or persistent abdominal pain. Allergic reactions like rash, itching, or swelling of the face also warrant prompt attention.
Individuals who are pregnant, breastfeeding, or have known allergy to Daclatasvir Dihydrochloride should avoid its use. Patients with severe liver impairment may require special consideration before starting therapy.
Alcohol consumption can increase liver strain while using this medication. Certain other antiviral drugs and medicines that affect liver enzymes may alter its effectiveness; always check the medication label or package information for specific interaction details.
Before starting a course, patients should store the tablets in a dry place away from direct sunlight and keep them out of reach of children. Typical treatment durations range from 12 to 24 weeks, depending on the combination of medicines used and the severity of liver disease.
Natcad and Daclatasvir may differ slightly in tablet strength and packaging, but both deliver the same active ingredient.
For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This article provides an educational overview of Daclatasvir Dihydrochloride and is not medical advice. Medicines containing this active ingredient, such as Natcad and Daclatasvir, may differ in formulation, strength, and directions. The information presented does not replace professional clinical judgment, and we accept no liability for how it is applied. Readers should review the labeling of their specific medication and seek guidance from a healthcare professional.
Additional details can be found through the following sources:
